The size of the Vaccine Adjuvant Market in the Asia Pacific was worth $104.3 million in 2019 and estimated to be growing at a CAGR of 11.73%, to reach $181.61 million by 2024.
Vaccine adjuvants are desirable to expand the adaptive immune reactions to antigens. Adjuvants show their effects through diverse mechanisms. Some adjuvants work as delivery systems that provide stimulation of the immune system. Immunologic adjuvants are added to vaccines for the stimulus of the reaction of immune system to the target antigen, but directly do not offer immunity. Adjuvants may act in several ways to present an antigen in the immune system. Adjuvants may also act as the annoyance to involve and intensify the body immune response.
Factors driving the world vaccine adjuvants market are increasing funding of government in R&D, high occurrence of diseases, growing emphasis on enriched vaccines, and strategic progressive moves assumed by companies such as contracts, acquisitions, and associations.
However, side effects of adjuvants and cost of adjuvant growth restrict the market growth.
This research report segmented and sub-segmented into the following categories:
On the basis of route of administration, the intramuscular segment is expected to account for the largest share of the global vaccine adjuvants market in 2018
Regionally, China and India being developing countries with an increase in population are estimated to grow at the highest CAGR in the forecast period.
Leading companies operating in the APAC Vaccine Adjuvant Market profiled in this report are MPV Technologies, Avanti Polar Lipids, Novavax Inc. Brenntag Biosector, SEPPIC, Agenus, Inc., Invivogen, SPI Pharma, Inc., CSL Limited and OZ Biosciences.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Aluminium Salts
5.1.2 Tensoactive Adjuvants
5.1.3 Adjuvant Emulsions
5.1.4 Bacteria derived Adjuvants
5.1.5 Liposome Adjuvants
5.1.6 Carbohydrate Adjuvants
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Intradermal
5.2.3 Subcutaneous
5.2.4 Intranasal
5.2.5 Intramuscular
5.3 By Mechanism of Action
5.3.1 Immuno Stimulants
5.3.2 Carriers
5.3.3 Vehicle Adjuvants
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 MPV Technologies
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Avanti Polar Lipids
8.3 Novavax Inc.
8.4 Brenntag Biosector
8.5 SEPPIC
8.6 Agenus, Inc.
8.7 Invivogen
8.8 SPI Pharma Inc.
8.9 CSL Limited
8.10 OZ Biosciences
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
